Smallpox vaccine safety is dependent on T cells and not B cells.
|
| Abstract |
The licensed smallpox vaccine, ACAM2000, is a cell culture derivative of Dryvax. Both ACAM2000 and Dryvax are administered by skin scarification and can cause progressive vaccinia, with skin lesions that disseminate to distal sites. We have investigated the immunologic basis of the containment of vaccinia in the skin with the goal to identify safer vaccines for smallpox. Macaques were depleted systemically of T or B cells and vaccinated with either Dryvax or an attenuated vaccinia vaccine, LC16m8. B cell depletion did not affect the size of skin lesions induced by either vaccine. However, while depletion of both CD4(+) and CD8(+) T cells had no adverse effects on LC16m8-vaccinated animals, it caused progressive vaccinia in macaques immunized with Dryvax. As both Dryvax and LC16m8 vaccines protect healthy macaques from a lethal monkeypox intravenous challenge, our data identify LC16m8 as a safer and effective alternative to ACAM2000 and Dryvax vaccines for immunocompromised individuals.
|
|---|---|
| Authors | Shari N Gordon, Valentina Cecchinato, Vibeke Andresen, Jean-Michel Heraud, Anna Hryniewicz, Robyn Washington Parks, David Venzon, Hye-kyung Chung, Tatiana Karpova, James McNally, Peter Silvera, Keith A Reimann, Hajime Matsui, Tomomi Kanehara, Yasuhiko Shinmura, Hiroyuki Yokote, Genoveffa Franchini |
| Journal | The Journal of infectious diseases (J Infect Dis) Vol. 203 Issue 8 Pg. 1043-53 (Apr 15 2011) ISSN: 1537-6613 [Electronic] United States |
| PMID | 21450994 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't) |
| Copyright | Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!